|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu WJ, Zhu KL, Xu J, Wang JL and Zhu H:
Enediyne-activated, EGFR-targeted human β-defensin 1 has
therapeutic efficacy against non-small cell lung carcinoma. Lab
Invest. 98:1538–1545. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu J, Du Y, Liu XJ, Zhu BY, Zhang SH, Li
L, Li Y, Wang XF, Shan CK, Wang RQ and Zhen YS: Recombinant
EGFR/MMP-2 bi-targeted fusion protein markedly binding to
non-small-cell lung carcinoma and exerting potent therapeutic
efficacy. Pharmacol Res. 126:66–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun YW, Xu J, Zhou J and Liu WJ: Targeted
drugs for systemic therapy of lung cancer with brain metastases.
Oncotarget. 9:5459–5472. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen R, Umeano AC, Chen P and Farooqi AA:
Polymer-based drug delivery systems for cancer. Crit Rev Ther Drug
Carrier Syst. 35:521–553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Basu U, Banik B, Wen R, Pathak RK and Dhar
S: The platin-X series: Activation, targeting, and delivery. Dalton
Trans. 45:12992–13004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pathak RK, Wen R, Kolishetti N and Dhar S:
A prodrug of two approved drugs, cisplatin and chlorambucil, for
chemo war against cancer. Mol Cancer Ther. 16:625–636. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wysoczynski M and Ratajczak MZ: Lung
cancer secreted microvesicles: Underappreciated modulators of
microenvironment in expanding tumors. Int J Cancer. 125:1595–1603.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blanco D, Vicent S, Fraga MF,
Fernandez-Garcia I, Freire J, Lujambio A, Esteller M,
Ortiz-de-Solorzano C, Pio R, Lecanda FJ and Montuenga LM: Molecular
analysis of a multistep lung cancer model induced by chronic
inflammation reveals epigenetic regulation of p16 and activation of
the DNA damage response pathway. Neoplasia. 9:840–852. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JI and Burckart GJ: Nuclear factor
kappa B: Important transcription factor and therapeutic target. J
Clin Pharmacol. 38:981–993. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tak PP and Firestein GS: NF-κB: A key role
in inflammatory diseases. J Clin Invest. 107:7–11. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dixit V and Mak TW: NF-kappaB signaling:
Many roads lead to Madrid. Cell. 111:615–619. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghosh S and Karin M: Missing pieces in the
NF-kappaB puzzle. Cell. 109 (Suppl):S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Naumann M and Scheidereit C: Activation of
NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO
J. 13:4597–4607. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sakurai H, Chiba H, Miyoshi H, Sugita T
and Toriumi W: IkappaB kinases phosphorylate NF-kappaB p65 subunit
on serine 536 in the transactivation domain. J Biol Chem.
274:30353–30356. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Badea T, Niculescu F, Soane L, Fosbrink M,
Sorana H, Rus V, Shin ML and Rus H: RGC-32 increases p34CDC2 kinase
activity and entry of aortic smooth muscle cells into S-phase. J
Biol Chem. 277:502–508. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schlick SN, Wood CD, Gunnell A, Webb HM,
Khasnis S, Schepers A and West MJ: Upregulation of the cell-cycle
regulator RGC-32 in Epstein-Barr virus-immortalized cells. PLoS
One. 6:e286382011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang JN, Shi N, Xie WB, Guo X and Chen SY:
Response gene to complement 32 promotes vascular lesion formation
through stimulation of smooth muscle cell proliferation and
migration. Arterioscler Thromb Vasc Biol. 31:e19–e26. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo X, Jose PA and Chen SY: Response gene
to complement 32 interacts with Smad3 to promote
epithelial-mesenchymal transition of human renal tubular cells. Am
J Physiol Cell Physiol. 300:C1415–C1421. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao
HZ, Li DM and Zhao Q: Response gene to complement-32 enhances
metastatic phenotype by mediating transforming growth factor
β-induced epithelial-mesenchymal transition in human pancreatic
cancer cell line BxPC-3. J Exp Clin Cancer Res. 31:292012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang JM, Shi N, Dong K, Brown SA, Coleman
AE, Boegehold MA and Chen SY: Response gene to complement 32
maintains blood pressure homeostasis by regulating α-adrenergic
receptor expression. Circ Res. 123:1080–1090. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Badea TC, Niculescu FI, Soane L, Shin ML
and Rus H: Molecular cloning and characterization of RGC-32, a
novel gene induced by complement activation in oligodendrocytes. J
Biol Chem. 273:26977–26981. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim DS, Lee JY, Lee SM, Choi JE, Cho S and
Park JY: Promoter methylation of the RGC32 gene in nonsmall cell
lung cancer. Cancer. 117:590–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Njikan S, Manning AJ, Ovechkina Y, Awasthi
D and Parish T: High content, high-throughput screening for small
molecule inducers of NF-κB translocation. PLoS One.
13:e01999662018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pahl HL: Activators and target genes of
Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jalili A, Wagner C, Pashenkov M, Pathria
G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G,
et al: Dual suppression of the cyclin-dependent kinase inhibitors
CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst.
104:1673–1679. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu J, Li X, Kong X, Moran MS, Su P,
Haffty BG and Yang Q: Testin is a tumor suppressor and prognostic
marker in breast cancer. Cancer Sci. 103:2092–2101. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kravtsova-Ivantsiv Y, Shomer I,
Cohen-Kaplan V, Snijder B, Superti-Furga G, Gonen H, Sommer T, Ziv
T, Admon A, Naroditsky I, et al: KPC1-mediated ubiquitination and
proteasomal processing of NF-κB1 p105 to p50 restricts tumor
growth. Cell. 161:333–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fosbrink M, Cudrici C, Niculescu F, Badea
TC, David S, Shamsuddin A, Shin ML and Rus H: Overexpression of
RGC-32 in colon cancer and other tumors. Exp Mol Pathol.
78:116–122. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu Y and Hu XB: C5a stimulates the
proliferation of breast cancer cells via Akt-dependent RGC-32 gene
activation. Oncol Rep. 32:2817–2823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu R, Shang C, Zhao J, Han Y, Liu J, Chen
K and Shi W: Knockdown of response gene to complement 32 (RGC32)
induces apoptosis and inhibits cell growth, migration, and invasion
in human lung cancer cells. Mol Cell Biochem. 394:109–118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jo H, Zhang R, Zhang H, McKinsey TA, Shao
J, Beauchamp RD, Ballard DW and Liang P: NF-kappaB is required for
H-ras oncogene induced abnormal cell proliferation and
tumorigenesis. Oncogene. 19:841–849. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen W, Li Z, Bai L and Lin Y: NF-kappaB
in lung cancer, a carcinogenesis mediator and a prevention and
therapy target. Front Biosci (Landmark Ed). 16:1172–1185. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tichet M, Prod'Homme V, Fenouille N,
Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi
S, Giacchero D, et al: Tumour-derived SPARC drives vascular
permeability and extravasation through endothelial VCAM1 signalling
to promote metastasis. Nat Commun. 6:69932015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen PH, Chang H, Chang JT and Lin P: Aryl
hydrocarbon receptor in association with RelA modulates IL-6
expression in non-smoking lung cancer. Oncogene. 31:2555–2565.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Naik NA, Bhat IA, Afroze D, Rasool R, Mir
H, Andrabi SI, Shah S, Siddiqi MA and Shah ZA: Vascular endothelial
growth factor A gene (VEGFA) polymorphisms and expression of VEGFA
gene in lung cancer patients of Kashmir Valley (India). Tumour
Biol. 33:833–839. 2012. View Article : Google Scholar : PubMed/NCBI
|
